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Summary
The effects of purified recombinant interleukin 7 (IL7) on the generation of cytolytic T lymphocytes
(CTL) in mixed lymphocyte culture (MLC) and on the induction oflymphokine-activated killer
(LAK) cells in autologous cultures of humanperipheral blood mononuclear cells were investigated.
IL7 was found to induce the generation ofboth CTL and LAK cells in bulk cultures. The appearance
of peak CTL activity in MLC established with exogenous IL-7 was delayed in comparison with
replicate cultures containing exogenous IL2, but both cytokines stimulated quantitatively similar
levels of antigen-specific lytic activity. An IL2-neutralizing antiserum inhibited substantially,
but not completely, the effect of IL7 on CTL generation, implying the existence of both an
indirect component of 11,7 activity via IL2 utilization, as well as an IL2-independent component.
Cell surface phenotypic analysis of 11,2- or IL7-generated CTL effector cells revealed that CD8+
cells were responsible for the vast majority of lytic activity. Limiting dilution analysis (LDA)
revealed that essentially identical frequencies of CTL precursors (CTLP) were capable of clonal
expansion and/or differentiation in the presence of exogenous IL2, 114, or IL7, supporting
the concept that all three of these cytokines are capable of exerting a major influence on T cell
growth and differentiation. Approximately half of the CTLP that responded in IL7-supplemented
LDA cultures did so in an IL2-independent manner. IL7 stimulated the development of LAK
cells in autologous bulk cultures, but only weakly in comparison with IL2. In contrast to its
effects on CTL generation, the induction of LAK cells by 11,7 was virtually independent of
IL-2. LAK cells induced by IL7, like those induced by 11,2, were phenotypically heterogeneous
and included CD8+, CD56+, and -y/S+ cells. Limiting dilution analysis indicated that 1172
stimulated fivefold more LAK-P than IL7 and 220-fold more than 1174. Collectively, these data
suggest that 11,7 has potent regulatory effects on human cytolytic cell populations and, either
alone or in combination with other cytokines, could be important for the in vitro expansion
of cells for adoptive immunotherapy.
Activation of resting T lymphocytes into cytolytic cells
1-1 normally requires both interaction with processed an-
tigen through the TCR complex and the collaborative ac-
tion of soluble cytokines (1). Among the cytokines with
reputed rolesin T cell proliferation and/or differentiation are
IL-1, -2, -4, -5, and -6, TNF, IFN-y, and granulocyte-macro-
phage CSF (2-8) . The most recent addition to the list of
T cell-active cytokines was IL-7. IL-7 was originally purified
and its cDNA cloned based upon the ability to cause the
growth of pre-B cells (9) . More recently, it has been shown
to be a potent costimulus for the proliferation of mitogen-
activated murine and human T cells (10-13). Notably, IL7
has been shown to expand numerically both CD4+ and
CD8+ T cells. The cytokine IL-2, in addition to promoting
the growth and differentiation of T cells, including CTL,
also has been shown to induce a killer cell population in the
absence of overt antigen that is able to lyse fresh tumor cells
and NK-resistant tumor cell lines (14). These cytolytic cells,
termed lymphokine-activated killer (LAK)t cells, are also
regulated in both a positive and negative manner by other
cytokines, including IL-4 (15-18).
In this study, we assessed the activity of purified rIL7 on
the generation of CTL from human PBL in MLC, and on
the induction of LAK cells in autologouscultures, both alone
and in combination with IL-2 and IL-4. Exogenous IL-7 was
'Abbreviations used in this paper. CTITP, CTL precursor; LAK,
lymphokine-activated killer; LDA, limiting dilution analysis.
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ationwith activity equivalent to IIT2. However, optimal lytic
activity generated by IL-7 was detected later than in cultures
supplemented with IL2. Theeffect of IL7on the generation
of CTL couldbe partially inhibited by antibodies against ILL
2, though there remained a portion of IL2-independent ac-
tivity. IL-7 also induced LAK cells in cultures containing no
overt antigenic stimulus, but did so far less efficiently than
IL-2. In contrast to the generation of CTL, the induction
ofLAK activity by IL-7 wasnot inhibitedby anti-IL-2. Thus,
the effects of 11,7 on the development of cytolytic cells in
vitroappear to have both IL-2-dependent and IL-2-independent
components, depending upon the culture system (MLC vs.
autologous) andcorrespondingcell types (CTL vs. LAK) in-
volved. These results implicate IL-7 as an important regula-
tory cytokine in human lymphocyte growth and differen-
tiation.
Materials and Methods
Cell Cultures.
￿
PBMC were isolated from heparinized blood by
centrifugation over Ficoll-Hypaque and washed three times with
culture medium. Culturemedium consistedofRPMI 1640 (Gibco
Laboratories, GrandIsland, NY)supplemented with 10% FCS (Hr
cloneLaboratories, Logan, UT), 50 U/ml penicillin, 50 leg/ml strep-
tomycin, 2 mM glutamine and 5 x 10-5 M 2-ME. 106 PBMC
were cultured with 106 irradiated stimulating cells (3,500 rad,
using a 131CS source) in 16-mm wells (3524; Costar, Cambridge,
MA)in 2 ml ofculture medium. Cultures were incubated at 37°C
in 5% COZfor 7-14 d. The tumorcell lines Daudiand K562 were
obtained from the American Type Culture Collection (Rockville,
MD) and maintained in continuous passage.
Cytokines.
￿
Human rIL2 andrIL4 were purified from superna-
tantsofyeastcellsexpressing thecorresponding cDNA as described
previously (15, 19). Purified IL2 had a specific activity of 3 x 105
U/Itg in theCTLL assay (20) . Purified IL-4 had a specific activity
of 104 U/p,g in a B cell comitogenesis assay (15).
A human IL-7 cDNA was cloned as previously described (21)
and expressedin Escherichia coli. IL-7 was extracted from an E. coli
cell paste by soaking the cells in 6 M guanidine HCl, 0.15 M so-
dium sulfite, 0.05 M potassium tetrathionate, 0.1 M Tris, pH 8,
for 16 h at room temperature. The resulting lysate was clarified
by centrifugation (30,000 g, 30 min, 20°C) andapplied to acolumn
ofNTA-Sepharose (22). Thecolumn was washed with 6 M guani-
dine HCI, 0.1 MTris, pH 8, and then eluted with 6 M guanidine
HCI, 1% acetic acid. The purified IL-7 was then refolded and dia-
lyzedto 50 mM sodium phosphate, pH 7.2. Protein concentration
was determined by amino acid analysis and biological activity was
determined using the murine pre-B cell assay (9). Specific activity
of IL-7 expressed in E. coli and mammalian cells was equivalent.
Cytotoxicity Assay.
￿
A 4-h "Cr release assay was used to assess
cytolytic activity of cultured cells, as previously described (15).
Briefly, tumorcell lines or PBMC cultured for3dwith PHA (PHA
blasts) were radiolabeled by incubation with 100 j.Ci of "Cr for
1 h at 37°C. Cell cultures to be assessed forrytolytic activity were
washed twice in culture medium and serially diluted in 96-well
Vbottomed plates (3896; Costar). "Cr-labeled targets (2 x 103)
were added to make a final volume of 0.2 ml/well. After 4 h at
37°C, plates were centrifuged (150 g for 5 min), and 150 Id of
supernatant were harvested from each well. "Cr content of super-
natants was determined using an Auto gamma counter (5780;
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Packard Instrument Co., Downers Grove, IL). 1 LU was defined
as the fraction of the initial culture giving rise to 25 or 50% lysis
of thetarget cell population (PHA blasts andDaudi, respectively),
and was determined from dose-response curves. Percent specific
"Cr release was calculated according to the formula: 100x (ex-
perimental cpm - spontaneous cpm)/(maximum cpm - sponta-
neous cpm), where spontaneous cpm . = cpm released in the ab-
sence of effector cells and maximum cpm = cpm released in the
presence of 1 N HCI.
Anti-IL2 Serum. A rabbit antiserum raised against purified
humanrIL2wasused to neutralize IL-2 bioactivity. Theantiserum
was used at a 1:500 dilution, a concentration that could totally
neutralize up to 10 ng/ml of IL-2 activity.
Limiting Dilution Analysis (LDA).
￿
Limiting numbers of re-
sponding cells (ranging from 10 to 10,000 cells/well) were cultured
in 24 replicates per cell concentration in 96-well round-bottomed
microtiter plates (25850; CorningGlassWorks, Coming, NY)with
105 irradiated, autologous (LAK-P analysis) or allogeneic (CTLP
analysis) PBMC. After a 13-14-dincubation, theculture superna-
tants were removed and the cellular contents of individual wells
were resuspended in 100p,l of fresh medium . Thecells were then
transferred to the wells of V -bottomed plates, and 2 x 103 "Cr-
labeled targets in 100td of medium were addedper well. The E/T
mixtures were incubated in a 4-h "Cr release assay, as described
above.
Statistical Analysis.
￿
CTLP and LAK-P frequencies were deter-
mined from the Poisson distribution relationship between the
number ofcellspermicroculture andthepercent cytolyticallynega-
tive microcultures using the minimum Xz method, as described
by Taswell (23). Cultures were considered positive if the specific
"Cr release exceeded by 3 SD the mean background "Cr release
exhibited by control cultures comprisedoffeeder cells with cytokines
but no responding cells.
Separation ofEffector CellSubsetsbyImmunoadsorbentPanning.
￿
The
following murine mAbs against human cell surface antigens were
used forimmunoadsorbent panning: OKT4 (CD4), OKTS (CD8),
Leu-19 (CD56, expressed on NK cells and cytotoxic T cells that
mediate non-MHC-restricted cytotoxicity; Becton Dickinson &
Co., Mountain View, CA), and TCR-61 (recognizing theS chain
of the TCR; T Cell Sciences, Cambridge, MA). Cells were sus-
pended in 100 /.l ofculture medium supplemented with 10 jig/ml
of mAb at 4°C. After 30 min, cells were washed three times with
PBScontaining 1% FCS. Labeledcells were then incubatedon plastic
petri dishes that hadpreviously been coated with goat anti-mouse
IgG (Sigma Chemical Co., St. Louis, MO) at 5 p,g/ml for 2 h.
Petri dishes were incubated at 4°C for40 min. Nonadherent cells
were collected by washing gently three times with 3 ml of PBS
containing 1% FCS. Adherent cells were recovered using a cell
scraper and collected by washing. Isolated cell populations were
assessed for purity by flow cytometry.
Results
11,7 Augments Antigen-Specific CTL Generation.
￿
Freshly
isolated PBMC from human donorVB were cultured in MLC
in the presence ofirradiated stimulating cellsfrom allogeneic
donor KB and 10 ng/ml of either human rII,2 or human
rIL7. Cytolytic activity against PHA blasts was assessed at
day 7 using a 4-h 5'Cr release assay. Culture of cells from
these two donors in MLC under the conditions used in this
study results in a detectable but weak CTLresponse that can
be augmented significantly by cytokines that promote CTL
development (15). Addition of either IL2 or IL -7 at the be-Cell cultures were established with 106 VB effector cells and 106
irradiated VB- or KB-stimulating cells. IL-2 or IL-7 was added at
10 ng/ml, and cultures were assessed for cytolytic activity at day 7
against 5'Cr-labeled KB or VB PHA blasts or Daudi target cells.
' Data represent LU per culture. LU were calculated from the dose-
response curves (see Figs. 1 and 2) using 25% specific 5'Cr release
for KB and VB PHA blasts and 50% specific 5'Cr release for Daudi
targets. The lysability of VB targets was previously established with
a control KB anti-VB culture supplemented with IL-2, which ex-
hibited >150 LU of anti-VB activity.
ginning of culture significantly enhanced the generation of
cytolytic activity against KB targets prepared from the
stimulating cell donor, when compared with cultures con-
taining no exogenous cytokine (Fig. 1). As shown in Table
1, anti-KB lytic activity recovered on day 7 of VB anti-KB
MLC was enhanced -200-foldby inclusionof exogenousIL-2
in culture, and 60-fold by IL7 in comparison with cultures
containing no exogenous cytokine. In a series of five iden-
tical experiments where VB responding cells were cultured
with irradiated KB-stimulating cells andassayed forlytic ac-
tivity against KB PHA blast targets at day 7-10, nonsup-
plemented cultures contained an average of -1 LU/culture
(range, <1-2), compared with 49 LU/culture for IL-7-
supplemented cultures (range, 16-88) and 115 LU/culture for
IL-2-supplemented cultures (range, 28-215). In addition, CTL
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Cell cultures were established with 106 responding cells and 106 stimulating cells. Cytokines (10 ng/ml)
and cytolytic activity was tested against 5'Cr-labeled PHA blasts on day 9.
' Results are expressed as LU per culture.
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Figure 1.
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Enhancement of CTL generation in MLC by IL7 and LL*2.
VB anti-KB MLC were supplemented with 10 ng/ml of either 11,2
or IL.7 and assayed at day 7 for their ability to lyse 5'Cr-labeled PHA
blasts from donor KB in a 4-h 51Cr release assay. Cell recoveries were
92% for nonsupplemented cultures and 270 and 208%, respectively,
for 11,2- and IL,7-supplemented cultures.
generated in either IL-2- or IL-7-supplemented MLC were
specific for KB targets in that they were unable to cause
significant lysis of control VB targets syngeneic with the re-
sponding cell donor. Table 2 shows the results of an experi-
ment with three different blooddonors. In allcases, the gener-
ationoflyticactivity against PHAblast target cells from the
stimulating cell donor was significantlyenhanced (>100-fold)
by the addition of either IL2 or IL7. As anticipated, cross-
reactive lytic activity against third-party targets was also en-
hanced by either IL-2 or 11,7, however, minimal lytic activity
was observed against target cells from the, responding cell
donor.
11,7 Stimulates the Formation of LAK Cells.
￿
Autologous
cultures of VB PBMC containing either IL-2 or IL-7 but no
overt antigen were assessed for cytolytic activity against the
LAK-sensitive, NK-resistant tumor cell line Daudi. Sup-
plementation of cultures with either IL2 or IL7 resulted in
the appearance of a LAK cell population that lysed Daudi
targets (Fig. 2). However, IL-7 induced 10-20-fold less LAK
activity per culture than did IL2 (Table 1) . In a series of five
were added at the initiation of culture
Table 2. IL-7
Culture
Enhances the
Medium
Generation of
Target LB
IL-2
Allospecfic
IL-7
CTL
Medium
Target MH
IL-2 IL-7 Medium
Target PS
IL-2 IL-7
LB anti-MH <1* <1 <1 <1 2,380 1,250 <1 238 238
LB anti-PS <1 <1 <1 <1 300 238 <1 323 526
MH anti-LB n-1 500 769 <1 <1 <1 <1 29 94
MH anti-PS ""-1 116 116 <1 <1 <1 <1 109 139
PS anti-LB <1 364 1,300 <1 98 455 <1 <1 <1
PS anti-MH 10 435 1,162 8 417 1,000 <1 <1 <1
Table 1. Effects of IL-2 and IL-7 on the Generation of
Human Cytolytic Cell Populations
m
d
Culture supplement
m
Target Culture Medium IL-2 IL-7
U
r
N
KB VB anti-KB ,-1* 208 59
V
VB anti-VB <1 -2 <1 d a
VB VB anti-KB <1 <1 <1
N
VB anti-VB <1 <1 <1
0
Daudi VB anti-KB <1 270 36
VB anti-VB <1 540 29m
w
d
d
U
100
80
60
40
20
0
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Figure 2.
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LAK activity is induced by 11,7. Autologous cultures
were established using VB effector cells and irradiated VB filler cells.
Cultures were supplemented with 10 ng/ml of either 11,2 or IL-7 and
assayed at day 7 for cytolytic activity against s'Cr-labeled Daudi
target cells. Cell recoveries were 57% for nonsupplemented cultures
and 167 and 156%, respectively, for 11,2- and 11r7-supplemented
cultures.
identical experiments where VB-responding cells were cul-
tured with autologous irradiated cells and assayed for lytic
activity against Daudi targets at day 7-10, nonsupplemented
cultures contained an average of tit LU/culture (range, <1-2),
compared with 21 LU/culture for IL7-supplemented cultures
(range, 15-29) and 352 LU/culture for IL-2-supplemented cul-
tures (range, 241-540). Similar results were obtained with
PBMC from several other donors (data not shown).
Kinetics of CTL and LAK Cell Generation by IL7.
￿
Table 3
shows data derived from a kinetics experiment in which the
lytic activity of allogeneic and autologous cultures was as-
sessed at days 7, 10, and 14. In IL2-supplemented cultures,
CTL activity was maximal at day 7 (215 LU) and gradually de-
creased by day 10 (143 LU) and day 14 (62 LU). The effect
of IL7 on the CTL response was delayed in comparison with
IL2 such that maximal activity (182 LU) was detected on
day 10. However, the levels of peak lytic activity arising in
cultures supplemented with either IL-2 or IL7 were similar.
In contrast to CTL activity, optimal LAK cell activity in-
duced by either IL2 or IL-7 was detected at day 10 (900 and
Table 3.
￿
Kinetics of CTL and LAK Cell Generation in
Cultures Supplemented with Either IL-2 or IL-7
CTL LAK
Culture
supplement Day 7 Day 10 Day 14 Day 7 Day 10 Day 14
Medium N2' 22 21 <1 N5
IL-2 215 143 62 480 900
IL-7 88 182 91 28 80
Cultures comprised 106 VB cells plus 106 irradiated KB cells for
CTL responses and 106 VB cells plus 106 irradiated VB cells for
LAK responses and were supplemented with 10 ng/ml of either
IL-2 or IL-7. Lytic activity was assessed against s1Cr-labeled KB
PHA blasts (CTL) or Daudi (LAK) targets at the indicated days.
' Data represent LU per culture.
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80 LU, respectively), however, at none of the time points
tested did the activity induced by IL7 approach that of IL2.
Dose-Response ofI1,2 andIL7 in CTL and LAK Cell Gener-
ation. The comparative efficiency of 11,2 and IL-7 in pro-
moting the generation of both CTL and LAK cells was ex-
amined by culturing PBMC in MLC or autologous cultures
with varying doses of cytokine and testing for lytic activity
12 d later. Table 4 shows that 11,2 enhanced CTL generation
when present at concentrations >1 ng/ml. In contrast, >10
ng/ml of 11,7 was required for a similar effect . However, in
terms of total lytic activity generated, IL-7 was at least as
effective as IL2 when present at 10 and 100 ng/ml, although
it should be noted that the day of assay (day 12) was more
optimal for detection of 11,7 effects than IL-2 effects (Table
3). Notably, both IL-2 and IL7 enhanced cell recovery to a
similar degree in allogeneic cultures. Cells were also stimu-
lated to proliferate by both cytokines in autologous cultures,
but to a lesser extent than in allogeneic cultures. The addi-
tion of 1 ng/ml or more of either IL -2 or IL-7 to autologous
cultures resulted in the development of significant cytotoxic
activity against either Daudi (NK-insensitive) or K562 (NK-
sensitive) target cells. However, in contrast to the similar effects
of these cytokines on CTL induction, IL-2 was far more po-
tent than IL-7 at inducing LAK cellsin terms of the maximal
amount of lytic activity generated per culture.
Induction ofProliferation by 11,7 Is Independent ofIL2.
￿
As
IL-2 is a potent inducer of both CTL and LAK cells, the effects
of IL-7 on cytolytic cells could conceivably be mediated via
the secondary production of IL2. To address this possibility,
we assessed the effects of an IL2-neutralizing antiserum on
the induction of cell proliferation, CTL, and LAK cells by
11,7. The anti-IL-2 serum was a potent inhibitor of the prolifer-
ative response in IL2-supplemented VB anti-KB cultures,
causing total ablation of [3H]thymidine incorporation in-
duced by 10 ng/ml of IL-2 (Fig. 3) . High concentrations of
IL2 (100 ng/ml) could overcome the inhibitory effects of the
anti-IL2 serum, suggesting the serum itself was not toxic.
In contrast, the induction of proliferation by IL-7 was virtu-
ally unaffected by the presence of anti-11,2, implying that
under these culture conditions IL-7-mediated proliferation is
independent of IL2.
Effects ofAnti-IL2 on the Induction ofCTL and LAK Cells
by either 11,2 or IL7. Fig. 4 shows that the anti-IL2 serum
inhibited substantially, but not totally, the effect of IL-7 on
the generation of CTL in MLC, reducing the lytic activity
from 88 LU per culture to 8 LU. In contrast, anti-IL-2 had a
limited effect on the induction of LAK cell activity by IL7,
reducing LU from 28 to 20. Similar results were obtained
if the cultures were assayed at either day 10 or day 14. In
control cultures, the anti=IL2 serum inhibited the IL-2-
mediated induction ofboth LAK cells and CTL to background
levels. Interestingly, lytic activity that developed in the ab-
sence of exogenously added cytokine was also suppressed by
anti-IL-2, suggesting that endogenously produced IL-2 is
responsible for such activity in these cultures. In addition,
IL-7-mediated induction of CTL and LAK cells was not
significantly affected by neutralizing antibodies against ei-
ther 11,4 or I1r6 (data not shown).Table 4.
￿
Dose-Response ofIL-2 and IL-7 in CTL and LAK Cell Generation
Cultures were established with 106 VB effector cells and either 106 irradiated KB (CTL) or VB (LAK) stimulator cells and supplemented
with the indicated dose of rIL-2 or rIL-7. Lyric activity against 51Cr-labeled KB PHA blasts (CTL), Daudi (LAK), or K562 (LAK) targets
was assessed at day 12-14. Values represent mean of two experiments.
Effect of11,7in Combination with Other Cytokines.
￿
We and
others have previously demonstrated regulatory effectsofother
cytokines on CTL generation and LAK cell induction. For
example, cytolytic activity induced by IL2 is strongly inhibited
by the early addition to cultureof IL4 (15-18). Consequently,
we assessed the effects of IL7 in combination with IL-2 and/or
IL4 on the generation of cytolytic cells. The data shown in
Table 5 confirm the inhibitory effect ofIL4 on IL2-promoted
generation of CTL and LAK cells. IL4 also inhibited the
induction ofLAKcellsby IL7. The inhibitory effects ofIL4
on LAK induction by either IL2 or IL7 did not appear to
be due to nonspecific cell toxicity or inhibition of cell growth,
as there was no consistent correlation between its inhibitory
effects on lytic activity and cell recoveries. Furthermore, the
development ofCTL activity in the presence of IL7 was not
impaired by the addition of 11,4. It should be notedthat 11,4
alone had weak activity in promoting CTL, in confirmation
of previously published results, although if its addition to
100 32 10 3 .2 1 .32 .1
IL-2 (nglml)
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MLC is delayed until day 3 or 4, it has activity equivalent
to IL-2 (15). The combination of IL-2 and IL -7 had virtually
identical effects on the generation ofboth populations of cyto-
lyticcells as IL2 acting alone. The patterns ofresponsiveness
observed at day 14 assay (data not shown) were essentially
similar to those observed at day 7 (Table 5). In addition, varying
the doses ofIL-2 and IL7 resulted in no evidence for synergy
between these two cytokines for either CTL enhancement
or LAK cell induction (data not shown) .
Characterization ofEffector Cells Mediating CTL and LAK
Activity. Experiments were performed to compare the cell
surface phenotype ofcells induced by either IL2 or IL-7 that
mediated lysis of specific CTL targets or LAK cell lysis of
Daudi targets. Autologous or allogeneic PBMC were cul-
tured for 9 d in the presence of 20 ng/ml of either IL-2 or
IL7. For CTL cultures, effector cells were separated into
CD4 - and CD4+, CD8 - and CD8+, or CD56 - and
CD56+ subsets by immunoadsorbent panning and assessed
Figure 3. Anti-IL-2 antibodies inhibit IL-2-
induced proliferation but not IL-7-induced pro-
liferation in MLC. 105 VB cells were cultured
with 105 irradiated KB cells in 200-P1 wells for
4 d in the presence of the indicated amounts of
IL2 or IL7, with (O) or without (") a con-
stant concentration of anti-11,2 serum (1:500).
[3H]Thymidine (1 FACi) was added for the last
16 h of culture. Values represent mean of tripli-
cate cultures. Thymidine incorporation by non
0
￿
cytokine-supplemented cultures was 1,673 cpm
and, in the presence of anti-11,2, was 975 cpm.
Culture supplement
Percent
recovery
CTL
LU2s/culture
Percent
recovery
LAK
LUso/culture
(Daudi targets)
LUso/culture
(K562 targets)
ng/ml
Medium 61 <1 66 <1 4
IL-2
0.1 78 <1 71 <1 6
1 92 10 83 18 68
10 194 25 178 115 210
100 663 118 296 312 530
IL-7
0.1 78 <1 64 4 12
1 102 ti1 62 12 31
10 319 33 197 28 68
100 424 214 182 55 810
O
O
Q
V
N
Y a
N
O
0
Q
U
N
w
o IL
(a
0
A O
O
0
v
v
Y a
IL-7
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forlytic activity against allogeneic targets (Table 6). It should
be noted that thelyticactivity measured forpositively selected
cells maybe underestimated due to nonquantitativerecovery
ofcellsboundto thepan, inhibition oflysisby antibody bound
IL-2
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Effect of anti-IL2 on the
generation ofCTLandon LAKcell induc-
tion. (A) VB anti-KB (CTL) or (B) VB
antiVB (LAK) cultures were supple-
mented with 10 ng/ml of either 11,2 or
11,7 in the presence (O) or absence (")
of an anti-IL2 serum. Cultures were as-
sessed at day 7 for lytic activity against
either s1Cr-labeled KB blasts or Daudi
cells.
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to the cells, or cell damage due to scraping. Among CTL
generated in the presence of either 11,2 or IIs7, the vast
majority of lytic activity was contained within the CD8+
population with no activity within the CD4+ cells. Among
Values represent mean of two experiments.
" VB cells were incubated with irradiated KB cells in the presence of various cytokines (used at 10 ng/ml). Lytic activity against s1Cr-
labeled PHA blasts from donor KB was assessed on day 7.
t VB cells were incubated with irradiated autologous filler cells and assessed for the ability to lyse s1Cr-labeled Daudi targets on day 7.
Table 5. Combinatorial
Cytokine(s) added
Effects ofIL-2, IL-4,
Percent recovery
and IL-7 on CTL Generation and LAK
CTL activity"
(LU2s/culture)
Cell Induction
LAK
Percent recovery
activity#
(LUso/culture)
- 56 3 44 <1
IL-2 156 142 101 350
IL-4 120 10 89 <1
IL-7 142 32 85 17
IL-2 + IL-4 159 56 69 35
IL-2 + IL-7 226 160 177 215
IL-4 + IL-7 145 50 118 N2
IL-2 + IL-4 + IL-7 158 42 130 36PS anti-MH MLC supplemented with either IL-2 or IL-7 were cultured for 9 d before separating into subpopulations of cells
sorbent panning and assaying for lytic activity against MH targets.
the IIT2-stimulated cells, the CD56+ population contained
a significant, though small, amount oflytic activity (42 LU),
whereas CD56+ cells from IIr7-supplemented cultures had
very weak lytic activity (4.4 LU).
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by immunoad-
To examinethecell surface phenotypeofLAKcells, effector
cells were divided into CD8- and CD8+, CD56 - and
CD56+, or y/6- and y/S+ subsets, and assessed for lytic
activity against Daudi targets (Table 7). As previously de-
VB PBMC were cultured with irradiated VB filler cells and supplemented with either IL-2 or IL-7. Cells were cultured for 8 d before sepa-
rating into subpopulations of cells by immunoadsorbent panning and assaying for lytic activity against Daudi targets.
Table 7. Characterization of Effector Cells Mediating LAK Activity
Percent cells staining for:
Stimulus Effector cells CD8 CD56 y/6 Total LU LU/106 cells
IL-2 Unseparated 38 19 6.0 139 147
CD8- 2.6 ND ND 74 141
CD8' 70 ND ND 24 165
CD56- ND 1.2 ND 32 33
CD56+ ND 67 ND 46 320
^y/S- ND ND 0.1 139 113
-Y/6' ND ND 85 5.0 223
IL-7 Unseparated 26 3.5 1.7 16 14
CD8- 1.0 ND ND 7.6 7.3
CD8+ 70 ND ND 2.4 8.4
CD56- ND 0.2 ND 4.6 3.8
CD56+ ND 72 ND 3.6 44
-Y/S- ND ND 0.1 2.8 3.9
'Y16+ ND ND 44 0.3 6.6
Table 6. Characterization of Effector Cells Mediating CTL Activity
Percent cells staining for:
Stimulus Effector cells CD4 CD8 CD56 Total LU LU/106 cells
IL-2 Unseparated 28 59 19 385 107
CD4- 12 70 ND 250 92
CD4+ 98 5.2 ND <0.1 <0.3
CD8- 66 4.0 ND 16 8.4
CD8* 5.7 98 ND 204 139
CD56 - ND ND 3.9 500 100
CD56' ND ND 99 42 290
IL-7 Unseparated 72 21 2.1 161 38
CD4- 30 54 ND 98 77
CD4* 95 1.0 ND -0.8 -0.6
CD8- 87 3.0 ND 8.3 2.9
CD8+ 6.0 97 ND 63 135
CD56 - ND ND 0.1 100 27
CD56' ND ND 98 4.4 109scribed (24-30), LAK effector cellswere phenotypically het-
erogeneous. LAK cells stimulated by either I1r2 or IL7 were
comprised of CD8+, as well as CD56+ and y/S+ cells. Un-
like CTL effector cells, greater lytic activity was found in
the CD8` than in the CD8+ cells. The most potently lytic
cells on a per cell basis were the CD56+ cells, which were
10-fold more lytic than their CD56 - counterparts. Cells ex-
pressing the TCRy/6 also exhibited significant lytic activity
on a per cell basis, though their overall contribution to the
totallytic activity was small due to their low numbers. Thus,
the cell surface phenotype of LAK cells induced by 11,2 or
11,7 was similar, with IL-2 inducing 10-fold greater lytic ac-
tivity in all cell populations tested.
Quantitation ofAlloreactive CTLP and Autologous LAKP
Frequencies in Limiting Dilution Cultures Supplemented with II,
2, IL4, or IL7. In these experiments, we wished to examine
directly the frequency of cytolytic progenitor cells from PBMC
that could respond to various cytokines. To this end, lim-
iting dilution cultures were established to allow estimation
of the frequency ofCTLP and LAK-P underconditions where
IL2, IT-4, or IL7 was used as a culture supplement to pro-
mote cellular activation and/or expansion. Limiting numbers
of VB-responding cells were cultured in the presence of 105
irradiated KB or VB cells and IL2, 114, or IL7 at 10 ng/ml.
After 13 or 14 d, microcultures were assessed for the ability
to lyse "Cr-labeled KB PHA blasts (allogeneic cultures) or
Daudi targets (autologous cultures) . As shown in Table 8,
nearly equivalent frequencies of CTLP were detected in al-
logeneic limiting dilution cultures supplemented with IL-2,
IL4, or IL7 (1:882 to 1:5,486), with IL4 activating a slightly
lower frequency than either IL-2 or IL7 . In contrast, the fre-
quency of CTLP detected in noncytokine-supplemented cul-
tures ranged from 1:75,000 to <1:240,000. Fig. 5 shows the
percent specific "Cr release exhibited by the 24 individual
replicate microcultures at each of the responding cell con-
centrations from experiment 1 (Table 8). Based upon the as-
sumptions that lytic activity depends on both the number
of cytolytic cells present in culture and the average lytic ac-
Table 8.
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tivity on a per cell basis, an average clone size can be esti-
mated from the data in Fig. 5. The average clone size was
calculated by dividing the sum of the percent specific 5'Cr
release for the positive wells from each experimental group
by the totalnumber of clones per group (calculated from the
Poisson equation) . The average size of CTL clones in lim-
iting dilution cultures stimulated with 11,4 or IL7 was similar
(11.6 and 10.4% specific lysis). The average clone size calcu-
lated for I1,2-supplemented cultures was somewhat greater
(19.2% specific lysis).
In contrast to CTLP, the frequency of LAK-P responsive
to the three cytokines differed markedly. IL2 induced 1:53
to 1:395 PBMC to give rise to cells that could lyse Daudi
targets. 11,7 induced fivefold fewer LAKP than 11,2. 11,4
was the weakest of the cytokines tested in this regard, in-
ducing 220-fold fewer LAK-P than IL2. Furthermore, only
very weak cytolytic activity was demonstrable among cyto-
lytically positive microcultures arising in IL4 compared with
either 11,2 or 11,7 (Fig. 5) . Thus, IL-2 and IL7 induced an
equivalent average LAK clone size (13.2 and 12.8% specific
5'Cr release, respectively), which far exceeded the average of
the few clones induced by 11,4 (3.2% specific 5'Cr release).
The addition of anti-11,2 serum to IL2- and 11,7-stimulated
limiting dilution cultures (Table 8, Exp. 3 and 4) had effects
similar to those seen in bulk cultures. Anti-IL-2 reduced the
frequency of both CTLP and LAKP detected in IL2-
supplemented cultures to background (medium alone) levels.
In contrast, anti-11,2 reduced the frequency of CTLP detected
in the presence of IL7 only two-fold, and had virtually no
effect on the frequency of LAK-P responsive to IL7.
Discussion
Recently it was reported that 11,7, described originally as
a pre-B cell growth factor, is also a potent costimulus for
the growth of both murine and human CD4+ and CD8+
T cells (10-13). In the experiments reported here, we inves-
tigated the effect of rIL7 on the generation ofCTL and LAK
Limiting numbers of VB responder cells were cultured with irradiated KB cells (CTL-P) or VB cells (LAK-P) and IL-2, IL-4, or IL-7 at 10
ng/ml. Results are expressed as frequency of precursor cells cytolytic for either KB PHA blasts (CTL-P) or Daudi targets (LAK-P) when tested
at day 13 or 14.
" Experiment number.
CTL-P LAK-P
Culture supplement 1" 2 3 4 1 2 3 4
- ND <1 :240,000 1:240,000 1:74,963 ND 1:99,834 <1:240,000 1:28,800
IL-2 1:1,691 1:882 1:1,149 1:1,634 1:53 1:58 1:395 1:192
IL-2 + anti-IL-2 ND ND <1:240,000 1:26,848 ND ND <1:240,000 1:240,000
IL-4 1:2,605 1:5,486 ND ND 1:9,801 1:14,978 ND ND
IL-7 1:1,332 1:1,782 1:1,691 1:2,511 1:460 1:319 1:1,325 1:566
IL-7 + anti-IL-2 ND ND 1:3,184 1:4,614 ND ND 1:1,132 1:647Figure 5 .
￿
Cytolytic activity of individual allogeneic (left) or autolo-
gous (right) microcultures supplemented with 11,2, 11,4, or 11,7 .
Limit dilution cultures were established as described for Table 5 . Data
show individual percent specific s'Cr release values for 24 replicate
CTL cultures (VB anti-KB) or LAK cell cultures (VB antiVB) at
various cell concentrations. The dotted lines indicate the mean plus 3
SD of the s 1Cr release by control cultures (feeder cells with rytokines
but no responding cells) .
cells from human peripheral blood . When IT-,7 was added
to MLC, it was found to enhance the generation of antigen-
specificCTL activity with potency similar to IIT2. Although
the two rytokines induced equivalent levels of lytic activity,
optimal CTL enhancement by IL7 occurred at a later time
in culture than noted for IL2 (day 10 vs. 7) . IL-7 was also
found to induce LAK cells in the absence of overt antigen,
but with substantially less potency than IL2 .
Given the known ability ofIL2 to promoteT cell growth
and differentiation, an obvious and important consideration
in the present studies concerns the role of IL2 as the actual
mediator of 11,7 effects . This possibility is particularly rele-
vant in view of the recent demonstration that IL7 induces
the p55 chain of the IL2R on murine and human T cells
(11, 12) . To address this issue, an antiserum against human
IL-2 was used in culture in conjunction with IL-7 . The anti-
11,2 serum had virtually no effect on the enhancement ofcell
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proliferation induced by IL7 in MLC, implying that this ac-
tivity of IL7 is independent of IL2 . However, the effect of
11,7 on CTL induction in MLC was found to be partially
inhibitable by the anti-L2 serum, suggesting that IL2 plays
a secondary role in these cultures. This finding is not sur-
prising in view of the fact that endogenous IL-2 is typically
produced when T cells are confronted with an antigenic
stimulus, as they are in MLC. Indeed, the fact that the anti-
IL2 serum reduced endogenous cell proliferation and both
CTL and LAK formation in the absence of added cytokine
suggests that low amounts of IL2 are produced in these cul-
tures. However, assay of culture supernatants for the pres-
ence of IL2 by the CTLL assay (20) failed to reveal higher
levels of IL-2 in IL-7-supplemented cultures when compared
with nonsupplemented cultures (data not shown) . These
results suggest that IL7 does not directly induce IL-2 produc-
tion . Furthermore, no synergy was observed between exoge-
nous IL-2 and IL7 in CTL induction (Table 5), and no en-
hanced response to IL-2 was observed in MLC pre-cultured
with IL7 for 3 d when compared with cells obtained from
pre-culture withmedium alone (data not shown) . In any event,
the fact that enhancement of CTL generation by IL-7 was
only partially inhibited by the IL-2-neutralizing agent sug-
gests that IL7 delivers a direct proliferative and/or differen-
tiative signal to at least someT cells . Alternatively, secondary
effects of rytokines other than IL2 may contribute to the
results. In this regard, neutralizing antibodies against either
IL4 or IL-6 were unable to inhibit the augmentation ofCTL
or induction of LAK cells by IL7 (data not shown) .
It is of interest that anti-IL-2 had virtually no effect on
cell proliferation in response to IL7, despite its effects on CTL
formation . These results are consistent with the possibility
that IL-2 or other rytokines may be responsible for the differen-
tiation and acquisition of cytolytic activity of some IL-7-
responsive cells.
In contrast to its effects on CTL generation, IL-7 was shown
to induce LAK cells in a largely IL-2-independent manner.
IL -7 thus joins I1r5 and IL-6 as cytokines that have recently
been shown to augment non-MHC-restricted killing by ei-
ther NK or LAK cells (31, 32) . However, both IL-5 and IL-6,
unlike IL7, appear to be dependent upon either exogenous
or endogenous IL2 for their activity on LAK orNK cells .
Considering the similar activities of IL2 and IL-7 in
promoting the generation ofCTL and LAK cells, it was of
interest to compare the surface antigen phenotype of the
effector cells mediating these two types of cytolysis. CTL
generated in the presence of either IL2 or IL-7 were almost
exclusively CD8+ cells, with a small contribution by
CD56+ (Leu-19+) cells in IL-2-stimulated cultures and al-
most negligible contribution by CD56+ cells in IL-7-
stimulated cultures. Precursors ofLAK cells have beenshown
to be comprised of several cell types, predominantly CD56+
NK cells and CD56+ T cells (24, 25) . More recently, T cells
expressing theTCR-y/S have been implicated in non-MHC-
restricted killing of NK and LAK cell targets (26-28) . We
found that effector cell populations stimulated by 11,2 or IL-7
and enriched for the expression of CD8 or CD56 or TCR-,y/b were all able to mediate lysis of LAK-sensitive Daudi
targets. However, similar to previous reports (24, 25), the
majority of lytic activity on a per cell basis was found within
the CD56+ population. In all the subpopulations of effector
cells tested, the lyticactivity ofIL7-stimulated cells was -10-
fold less than in IL2-stimulated cells. Thus, 11,7 appears to
act on the same lineages of cytolytic cells as IL-2, though
in the case of LAK cells with far less potency.
Limiting dilution analysis in which IL-2, IL-4, or IL-7 were
used to promote activation and clonal expansion revealed that
these three cytokines stimulated outgrowth of approximately
equivalent frequencies ofCTLP in allogeneic cultures. Clone
size estimates revealed that IL-2 induced CTL clones with
a somewhat greater average lytic activity than either IL4 or
IL7. Our results confirm and extend those of Paliard et al.
(29), who reported similar cloning efficiencies for human T
cells in either IL2 or IL-4. It is of interest that, at the bulk
culture level, IL4 is as effective as IL-2 in promoting CTL
generation if added late to culture but is far less effective when
added at the initiation of culture (Table 5 and reference 15).
The results demonstrating almost equal efficiency of11,2 and
IL4 in promoting clonal expansion of CTLP in limiting di-
lution cultures suggest that there is no requirement for delayed
addition of 11,4 when responding cell numbers are limiting.
Alternatively, IL-4 may activate an infrequent, inhibitory cell
type in bulk cultures that is not represented in limiting dilu-
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